Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by ...
These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...
Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
What's the impact on immune status, antioxidant capacity and acute phase proteins in 30 to 70 kg growing pigs?
The Biosimilars Market is set to witness a CAGR of 15% in the next 5 years. Impending patent expiry of blockbuster biologics, ...
Bladder cancer trials of antibody-drug conjugates may change the standard for neoadjuvant therapy away from dependence on cisplatin chemotherapy.
The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results